US, EU and UK Antitrust Enforcers Form Pharma Monitoring Taskforce
AZ’s planned Alexion acquisition may be an early target
Antitrust regulators in the US, Europe and elsewhere say they will now collaborate on how to best assess pharmaceutical mergers, in a move that could restrict deals on grounds they excessively raise prices paid by consumers or dampen medical innovation.
You may also be interested in...
The European Commission is investigating whether Teva has “abusively” blocked or delayed market entry of competitors to the company’s top selling multiple sclerosis drug.
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.
After the European Commission adopted a preliminary assessment that Aspen Pharmacare “may have abused its dominant position by imposing unfair prices” for six mature oncology brands, the South African firm has outlined multiple commitments that would bring to a close a three-year Commission investigation across the EEA if adopted.